Knight Therapeutics Inc.
GUD.TOTSXHealthcare● Active
$8.61
+$0.15(+1.77%)
Market Cap$844078767
P/E Ratio—
52W High$8.9
52W Low$5.66
Knight Therapeutics Inc. (GUD.TO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GUD.TO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.45B | $0.37B | $0.33B | $0.29B | $0.24B |
| Cost of Revenue | $0.30B | $0.20B | $0.18B | $0.16B | $0.13B |
| Gross Profit | $0.15B | $0.17B | $0.15B | $0.14B | $0.12B |
| Gross Margin %(computed) | 33.49% | 46.97% | 46.51% | 47.03% | 47.40% |
| Operating Expenses | |||||
| R&D Expenses | $0.03B | $0.02B | $0.02B | $0.01B | $0.01B |
| G&A Expenses | $0.00B | $0.05B | $0.04B | $0.04B | $0.04B |
| Total Operating Expenses | $0.15B | $0.17B | $0.16B | $0.16B | $0.13B |
| Operating Income | ($0.00B) | $0.01B | ($0.00B) | ($0.00B) | ($0.01B) |
| Operating Margin %(computed) | -0.49% | 1.99% | -0.88% | -0.82% | -2.19% |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| Income Before Tax | ($0.01B) | $0.00B | ($0.02B) | ($0.04B) | $0.01B |
| Income Tax Expense | ($0.00B) | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Net Income | ($0.01B) | $0.00B | ($0.02B) | ($0.03B) | $0.02B |
| Net Margin %(computed) | -1.19% | 1.17% | -5.13% | -10.18% | 6.44% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.05 | $0.04 | $-0.16 | $-0.26 | $0.13 |
| Wtd Avg Shares | 0.10B | 0.10B | 0.11B | 0.11B | 0.12B |
| EBITDA | $0.05B | $0.06B | $0.04B | $0.03B | $0.04B |
| EBITDA Margin %(computed) | 12.08% | 17.34% | 12.46% | 8.60% | 17.49% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CAD · B
Explore more Knight Therapeutics Inc. data
About Knight Therapeutics Inc. (GUD.TO) Income Statement
Knight Therapeutics Inc. (GUD.TO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GUD.TO reported revenue of $0.45B, gross profit of $0.15B (gross margin 33.49%), and net income of ($0.01B) — a net profit margin of -1.19%.
Frequently asked questions
GUD.TO · 4 questionsKnight Therapeutics Inc. (GUD.TO) reported revenue of $0.45B for 2025, up 21.2% year-over-year.
GUD.TO revenueGUD.TO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08